CompletedNot Applicable

Transparent Cap-assisted Endoscopic Sclerotherapy

China120 participantsStarted 2015-04

Plain-language summary

The aim of this study is to evaluate efficacy and safety of transparent cap-assisted endoscopic sclerotherapyI(lauromacrogol injection) in management of esophageal varices.

Who can participate

Age range18 Years – 76 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients presented to our hospital with esophageal varices diagnosed by gastroscopy, with or without gastric varices. * The age of the patients range from 18 to 80 years old. Exclusion Criteria: * Patients who have contraindications for lauromacrogol therapy or transparent cap. * Patients who have no previous upper gastrointestinal bleeding history. * Patients who have fecal disease that could greatly impact survival, such as uremia, advanced cancer or respiratory failure, et al.

What they're measuring

rebleeding rate

Timeframe: From date of randomization until the date of first rebleeding episode, assessed up to 1 month

Trial details

NCT IDNCT02361593

SponsorShanghai Zhongshan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Esophageal Varices trials